top of page
搜尋

FDA approves NRx preservative-free ketamine injection amid US hospital supply shortage

作家相片: nuaxia
nuaxia
11月2日
讀畢需時 2 分鐘

The FDA has approved NRx Pharmaceuticals' preservative-free generic ketamine injection, adding a US-manufactured supply option during an ongoing shortage of injectable ketamine.


The abbreviated new drug application covers a preservative-free ketamine formulation manufactured with Nephron Pharmaceuticals using blow-fill-seal technology and formulated without the preservative benzethonium chloride.


NRx reported that commercial supply was available following the 30 October approval announcement, although a specific launch date was not confirmed, and the decision applies to established anaesthesia uses rather than the company's separate investigational depression programme.

Field

Content

Article Type

Approvals

Company

NRx Pharmaceuticals

Manufacturing Partner

Nephron Pharmaceuticals

Product

Preservative-free generic ketamine injection

Active Ingredient

Ketamine

Product Type

Generic injectable medicine

Formulation

Preservative-free injection

Excluded Preservative

Benzethonium chloride

Manufacturing Technology

Blow-fill-seal

Manufacturing Geography

United States

Regulator

U.S. Food and Drug Administration

Approval Type

Abbreviated new drug application approval

Approval Announcement Date

30 October 2026

Approved Therapeutic Use

Established ketamine anaesthesia uses

Therapeutic Area

Anaesthesia

Administration Route

Injection

Supply Context

Ketamine injection listed on the FDA drug shortage list at the time of the announcement

Commercial Supply Status

NRx reported commercial supply on hand

Confirmed Commercial Launch Date

Not confirmed in supplied summary

Investigational Depression Programme

Separate from the approved generic anaesthesia product

Depression Indication Approval

No depression indication approval established by this announcement

Geographic Scope

United States

What Happened

The FDA approved an abbreviated new drug application for NRx's preservative-free generic ketamine injection.

Why It Matters

The approval adds a domestically manufactured injectable ketamine supply option during a reported US drug shortage.

Manufacturing Significance

The product uses blow-fill-seal technology and excludes benzethonium chloride.

Key Takeaway

NRx secured FDA approval for a preservative-free generic ketamine product for established anaesthesia uses, not for its investigational depression programme.

What to Watch

Confirmed commercial launch, hospital distribution, production capacity, shortage-list status and product availability.

Primary Source

NRx Pharmaceuticals

Primary Source URL

https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-receives-fda-approval

Relevant Date

30 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page